SI9420002B - Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin - Google Patents
Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin Download PDFInfo
- Publication number
- SI9420002B SI9420002B SI9420002A SI9420002A SI9420002B SI 9420002 B SI9420002 B SI 9420002B SI 9420002 A SI9420002 A SI 9420002A SI 9420002 A SI9420002 A SI 9420002A SI 9420002 B SI9420002 B SI 9420002B
- Authority
- SI
- Slovenia
- Prior art keywords
- salt
- methoxy
- use according
- medicament
- benzimidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
Abstract
Opisane so nove optično čiste spojine, ki so Na+, Mg2+, Li+, K+, Ca2+ in N+(R)4 soli (+)-5-metoksi-2-(((4-metoksi-3,5-dimetil-2-piridinil)metil)sulfinil)-1H- benzimidazola in (-)-5-metoksi-2-(((4-metoksi-3,5-dimetil-2-piridinil)metil) sulfinil)-1H-benzimidazola, v katerih je R alkil z 1-4 ogljikovimi atomi, postopek njihove priprave in njihova uporaba v izdelavi farmacevtskih pripravkov. Podani so tudi novi intermediati v pripravi spojin izuma.
Claims (13)
1 EP 1020461 BI Patentni zahtevki 1. Uporaba magnezijeve soli (-)-5-metoksi-2-[[(4-metoksi-3,5-dimetil-2-piridinil)metil]sulfinil-lH-benzimidazola ((-)-omeprazola) z optično čistoto oz. enantiomemim prebitkom (e.e.) >99,8 % za pripravo zdravila za inhibicijo izločanja želodčne kisline.
2. Uporaba po zahtevku 1, kjer je sol kristalinična.
3. Uporaba po zahtevku 1 ali 2, kjer je zdravilo za zdravljenje bolezni, povezane z želodčno kislino, in/ali gastrointestinalne vnetne bolezni.
4. Uporaba po zahtevku 3, kjer je bolezen gastrični ulkus, duodenalni ulkus, refluksni ezofagitis ali gastritis.
5. Uporaba po zahtevku 4, kjer je bolezen refluksni ezofagitis
6. Uporaba po zahtevku 1 ali 2, kjer je pacient na NSAID-terapiji, ima gastrinom in/ali akutno krvavitev zgornjega gastrointestinalnega trakta.
7. Uporaba po zahtevku 1 ali 2, kjer je zdravilo za zdravljenje pacienta v stanju intenzivne nege in/ali ga je treba uporabiti pred- in pooperativno za preprečenje kislinske aspiracije in stresne ulceracije.
8. Uporaba po zahtevku 1 ali 2, kjer zdravilo uporabimo pri zdravljenju infekcije s Helicobacter. 2
9. Magnezijeva sol (-)-5-metoksi-2-[[(4-metoksi-3,5-dimetil-2- piridinil)metil]sulfinil-lH-benzimidazola ((-)-omeprazola) z optično čistoto oz. enantiomemim prebitkom (e.e.) >99,8 %.
10. Sol po zahtevku 9 za uporabo pri terapiji.
11. Sol po zahtevku 10 za uporabo pri zdravljenju ali profilaksi stanja, kot je definirano v katerem koli od zahtevkov 3-8.
12. Sol po katerem koli od zahtevkov 9-11, ki je kristalinična.
13. Farmacevtski sestavek soli po katerem koli od zahtevkov 9-12 skupaj s farmacevtsko sprejemljivim nosilcem.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE19939301830A SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | New compounds |
PCT/SE1994/000509 WO1994027988A1 (en) | 1993-05-28 | 1994-05-27 | Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9420002A SI9420002A (en) | 1995-08-31 |
SI9420002B true SI9420002B (sl) | 2009-12-31 |
Family
ID=20390088
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9420002A SI9420002B (sl) | 1993-05-28 | 1994-05-27 | Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin |
SI9420085A SI22752B (sl) | 1993-05-28 | 1994-05-27 | Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9420085A SI22752B (sl) | 1993-05-28 | 1994-05-27 | Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin |
Country Status (43)
Families Citing this family (209)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
CN1138534C (zh) * | 1994-07-08 | 2004-02-18 | 阿斯特拉曾尼卡有限公司 | 多单元片剂 |
SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
HRP960232A2 (en) * | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
SE508669C2 (sv) * | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
SE510666C2 (sv) * | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
SE9702000D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
SE510643C2 (sv) * | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
EE04576B1 (et) * | 1997-12-08 | 2006-02-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Suposiit happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod, toimeaineühik ja selle valmistamismeetod ning preparaat |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
US20020039597A1 (en) * | 1998-04-20 | 2002-04-04 | Koji Ukai | Stabilized compositions containing benzimidazole-type compounds |
CN100396675C (zh) | 1998-08-10 | 2008-06-25 | 加利福尼亚州大学董事会 | 质子泵抑制剂的前药 |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9803772D0 (sv) | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
PT1131316E (pt) | 1998-11-18 | 2004-10-29 | Astrazeneca Ab | Processo quimico e formulacao farmaceutica melhorados |
SE9900274D0 (sv) * | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
TWI243672B (en) | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
EP1191948A2 (en) * | 1999-06-11 | 2002-04-03 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
US7094885B2 (en) * | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
US6262085B1 (en) * | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
EP1595879A3 (en) * | 1999-08-26 | 2010-01-27 | aaiPharma Inc. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
JP2003510348A (ja) * | 1999-10-01 | 2003-03-18 | ナトコ ファーマ リミテッド | 改良された薬学的組成物およびその製造方法 |
EP1222922B1 (en) * | 1999-10-20 | 2007-08-15 | Eisai R&D Management Co., Ltd. | Method for stabilizing benzimidazole compounds |
SE9903831D0 (sv) | 1999-10-22 | 1999-10-22 | Astra Ab | Formulation of substituted benzimidazoles |
PT1257269E (pt) | 2000-02-24 | 2005-03-31 | Kopran Res Lab Ltd | Derivados do benzimidazole anti-ulcera estavel em relacao ao acido de administracao oral |
SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
BR0110926A (pt) * | 2000-05-15 | 2004-02-17 | Ranbaxy Lab Ltd | Novas formas amorfas de sais de omeprazol e processo de preparação dos mesmos |
US6306435B1 (en) * | 2000-06-26 | 2001-10-23 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same |
CA2386716C (en) * | 2002-05-17 | 2012-07-24 | Bernard Charles Sherman | Magnesium salt of s-omeprazole |
AU2003204233B8 (en) * | 2000-08-04 | 2008-06-26 | Bernard Charles Sherman | Magnesium salt of S-omeprazole |
AU2001276721A1 (en) | 2000-08-04 | 2002-02-18 | Takeda Chemical Industries Ltd. | Salts of benzimidazole compound and use thereof |
US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
AU2002249935A1 (en) | 2001-01-08 | 2002-08-19 | Neorx Corporation | Radioactively labelled conjugates of phosphonates |
AU2002338655A1 (en) * | 2001-04-13 | 2002-10-28 | Aspinterm Llc | Methods of preparing sulfinamide and sulfoxides |
SE0101379D0 (sv) | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
GB2376231A (en) * | 2001-06-06 | 2002-12-11 | Cipla Ltd | Benzimidazole-cyclodextrin inclusion complex |
SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
EP1428825A4 (en) | 2001-09-18 | 2005-03-23 | Zeria Pharm Co Ltd | benzimidazole derivatives |
JP2005521662A (ja) * | 2002-01-25 | 2005-07-21 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤の経粘膜送達 |
DE60314105T2 (de) * | 2002-03-05 | 2008-01-24 | Astrazeneca Ab | Alkylammoniumsalze von omeprazol und esomeprazol |
CN100553625C (zh) | 2002-04-09 | 2009-10-28 | 弗拉梅技术公司 | 活性成分微囊的口服混悬液 |
US6894066B2 (en) * | 2002-05-09 | 2005-05-17 | Bernard Charles Sherman | Magnesium salt of S-omeprazole |
WO2004009583A2 (en) * | 2002-07-19 | 2004-01-29 | Garst Michael E | Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor |
TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
JP4634144B2 (ja) * | 2002-08-01 | 2011-02-16 | ニコックス エスエー | ニトロソ化プロトンポンプ阻害剤、組成物および使用方法 |
US7612098B2 (en) | 2002-08-30 | 2009-11-03 | Dr. Reddy's Laboratories Limited | Amorphous hydrous esomeprazole magnesium |
ES2534713T3 (es) | 2002-10-16 | 2015-04-27 | Takeda Pharmaceutical Company Limited | Preparaciones sólidas estables |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
AU2003278406A1 (en) * | 2002-10-22 | 2004-05-13 | Ranbaxy Laboratories Limited | Amorphous form of esomeprazole salts |
US20040242642A1 (en) * | 2002-11-18 | 2004-12-02 | Dr. Reddy's Laboratories Limited | Crystalline esomeprazole compounds and process for the preparation thereof |
DE10254167A1 (de) | 2002-11-20 | 2004-06-09 | Icon Genetics Ag | Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen |
US7301030B2 (en) | 2002-12-06 | 2007-11-27 | Nycomed Gmbh | Process for preparing (S)-pantoprazole |
BRPI0310118B1 (pt) | 2002-12-06 | 2015-10-20 | Altana Pharma Ag | processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila |
FR2848555B1 (fr) | 2002-12-16 | 2006-07-28 | Negma Gild | Enantiomere(-)du tenatoprazole et son application en therapeutique |
US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
JP2006518751A (ja) * | 2003-02-20 | 2006-08-17 | サンタラス インコーポレイティッド | 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物 |
US20060247277A1 (en) * | 2003-02-28 | 2006-11-02 | Yatendra Kumar | Polymorphs of s-omeprazole |
AU2003238671A1 (en) * | 2003-04-10 | 2004-11-01 | Hetero Drugs Limitd | Novel crystalline forms of s-omeprazole magnesium |
US20070060556A1 (en) * | 2003-05-05 | 2007-03-15 | Yatendra Kumar | Barium salt of benzimidazole derivative |
WO2004099182A1 (en) * | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Zinc salt of (s)-omeprazole |
NZ544173A (en) * | 2003-07-15 | 2009-04-30 | Alevium Pharmaceuticals Inc | Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors |
CA2531564C (en) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20050031700A1 (en) * | 2003-07-18 | 2005-02-10 | Sanatarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
MXPA06000652A (es) * | 2003-07-23 | 2006-03-30 | Altana Pharma Ag | Sales alcalinas de inhibidores de bomba de protones. |
CN100457104C (zh) * | 2003-07-23 | 2009-02-04 | 尼科梅德有限责任公司 | 质子泵抑制剂的碱性盐 |
US20060165793A1 (en) * | 2003-08-04 | 2006-07-27 | Koji Ukai | Pharmaceutical preparation to be dispersed before administration |
SE0302381D0 (sv) * | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts I |
SE0302382D0 (sv) * | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts II |
AU2003272081A1 (en) * | 2003-09-25 | 2005-04-11 | Natco Pharma Limited | Enteric soft gelatin capsule containing esomeprazole and method of preparation |
JP4919801B2 (ja) | 2003-09-26 | 2012-04-18 | アルザ・コーポレーシヨン | 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法 |
US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
AU2003272086A1 (en) * | 2003-10-14 | 2005-04-27 | Natco Pharma Limited | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation |
GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
US20070060621A1 (en) * | 2004-02-18 | 2007-03-15 | Hughes Patrick M | Methods and compositions for the administration of prodrugs of proton pump inhibitors |
JP2007523164A (ja) * | 2004-02-18 | 2007-08-16 | アラーガン、インコーポレイテッド | プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物 |
SE0400410D0 (sv) | 2004-02-20 | 2004-02-20 | Astrazeneca Ab | New compounds |
WO2005082888A1 (en) * | 2004-03-01 | 2005-09-09 | Milen Merkez Ilac Endustrisi A.S. | Process for the preparation of magnesium salt of omeprazole |
US7176319B2 (en) | 2004-04-28 | 2007-02-13 | Hetero Drugs Limited | Process for substituted sulfoxides |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
PT1748998E (pt) | 2004-05-28 | 2010-03-24 | Hetero Drugs Ltd | Novo processo de síntese estereoselectiva de sulfóxidos de benzimidazol |
US20050267159A1 (en) * | 2004-05-28 | 2005-12-01 | Aaipharma, Inc. | Magnesium complexes of S-omeprazole |
US20050267157A1 (en) * | 2004-05-28 | 2005-12-01 | David White | Magnesium-S-omeprazole |
CN103772360A (zh) * | 2004-06-24 | 2014-05-07 | 阿斯利康(瑞典)有限公司 | 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法 |
WO2006001755A1 (en) * | 2004-06-24 | 2006-01-05 | Astrazeneca Ab | A new esomeprazole sodium salt crystal modification |
US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
JP3921497B2 (ja) | 2004-08-06 | 2007-05-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ベンズイミダゾール誘導体とアミンとの塩およびその製造方法 |
KR100847635B1 (ko) * | 2004-08-06 | 2008-07-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 벤즈이미다졸 유도체와 아민과의 염 |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
WO2006066932A1 (en) * | 2004-12-24 | 2006-06-29 | Lek Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
US20060160783A1 (en) * | 2004-12-30 | 2006-07-20 | Transform Pharmaceuticals, Inc. | Novel omeprazole forms and related methods |
ES2259269B1 (es) | 2005-03-03 | 2007-11-01 | Esteve Quimica, S.A. | Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos. |
CA2597632C (en) | 2005-03-25 | 2012-05-15 | Livzon Pharmaceutical Group Inc. | Substituted sulfoxide compounds, methods for preparing the same and use thereof |
EP1885711A1 (en) | 2005-05-06 | 2008-02-13 | Glenmark Pharmaceuticals Limited | Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same |
EP1883405A4 (en) * | 2005-05-09 | 2010-01-27 | Takeda Pharmaceuticals North A | METHODS OF TREATING NEPHROLITHIASIS |
US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
US7563812B2 (en) | 2005-06-15 | 2009-07-21 | Hetero Drugs Limited | Amorphous esomeprazole hydrate |
KR100641534B1 (ko) | 2005-07-28 | 2006-11-01 | 한미약품 주식회사 | 에스오메프라졸 및 그의 염의 제조방법 |
CA2617248C (en) * | 2005-08-03 | 2015-09-29 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
US20070043085A1 (en) * | 2005-08-19 | 2007-02-22 | Glenmark Pharmaceuticals Limited | Process for the preparation of amorphous form of neutral esomeprazole |
WO2007031845A2 (en) * | 2005-09-14 | 2007-03-22 | Glenmark Pharmaceuticals Limited | Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation |
CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂 |
US7576219B2 (en) | 2005-10-26 | 2009-08-18 | Hanmi Pharm. Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
NZ568471A (en) | 2005-12-05 | 2010-09-30 | Astrazeneca Ab | New process for the preparation of esomeprazole non-salt form |
EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
US7553857B2 (en) | 2005-12-23 | 2009-06-30 | Lek Pharmaceuticals D.D. | S-omeprazole magnesium |
SI1973896T1 (sl) * | 2005-12-28 | 2009-08-31 | Union Quimico Farma | Postopek priprave (S) - enantiomere omeprazola |
US8063074B2 (en) | 2006-05-04 | 2011-11-22 | Dr. Reddy's Laboratories Limited | Polymorphic forms of esomeprazole sodium |
JP2009539830A (ja) * | 2006-06-07 | 2009-11-19 | アストラゼネカ・アクチエボラーグ | エソメプラゾールのアンモニウム塩の新規な製造方法 |
US7863330B2 (en) | 2006-06-14 | 2011-01-04 | Rottapharm S.P.A. | Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders |
BRPI0621832A2 (pt) | 2006-07-05 | 2013-03-19 | Lupin Ltd | processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido |
AU2007278986B2 (en) | 2006-07-25 | 2010-09-16 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI |
US20100317689A1 (en) * | 2006-09-19 | 2010-12-16 | Garst Michael E | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
EP2068841B1 (en) | 2006-10-05 | 2018-09-26 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
WO2008064015A1 (en) * | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
EP1947099A1 (en) | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
MX2009007680A (es) * | 2007-01-19 | 2011-08-03 | Takeda Pharmaceuticals North America Inc | Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios. |
WO2008092939A2 (en) * | 2007-01-31 | 2008-08-07 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
JP2010519284A (ja) | 2007-02-21 | 2010-06-03 | シプラ・リミテッド | エソメプラゾールマグネシウム二水和物の調製方法 |
KR101303813B1 (ko) * | 2007-04-16 | 2013-09-04 | 에스케이케미칼주식회사 | 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법 |
EP2000468A1 (en) * | 2007-05-09 | 2008-12-10 | Dr. Reddy's Laboratories Ltd. | Esomeprazole salts and processes for preparation thereof |
US8492551B2 (en) * | 2007-06-07 | 2013-07-23 | Aurobindo Pharma. Ltd. | Process for preparing an optically active proton pump inhibitor |
CN101323609B (zh) * | 2007-06-15 | 2013-05-01 | 成都福瑞生物工程有限公司 | 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法 |
WO2009040825A1 (en) | 2007-09-25 | 2009-04-02 | Hetero Drugs Limited | A process for preparation of enantiomerically pure esomeprazole |
WO2009047775A2 (en) * | 2007-10-08 | 2009-04-16 | Hetero Drugs Limited | Polymorphs of esomeprazole salts |
FR2925899B1 (fr) * | 2007-12-27 | 2012-12-21 | Sidem Pharma Sa | Procede de preparation enantioselective de sulfoxydes. |
EP2252274A4 (en) | 2008-02-20 | 2011-05-11 | Univ Missouri | COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME |
US20090280175A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Proton Pump Inhibitor Tablets |
US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
WO2009145368A1 (en) * | 2008-05-27 | 2009-12-03 | Sk Chemicals Co., Ltd. | Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent |
EP2143722A1 (en) * | 2008-07-09 | 2010-01-13 | Lek Pharmaceuticals D.D. | Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium |
EP2147918A1 (en) | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
KR20110079641A (ko) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법 |
EP2264024A1 (en) | 2008-10-14 | 2010-12-22 | LEK Pharmaceuticals d.d. | Process for the preparation of enantiomerically enriched proton pump inhibitors |
WO2010058409A2 (en) | 2008-11-18 | 2010-05-27 | Hetero Research Foundation | Optical purification of esomeprazole |
US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
WO2010097583A1 (en) | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
SG176724A1 (en) | 2009-06-25 | 2012-01-30 | Astrazeneca Ab | Method for treating a patient at risk for developing an nsaid-associated ulcer |
EA021112B1 (ru) * | 2009-06-25 | 2015-04-30 | Поузен Инк. | Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии |
EP2319504A1 (en) | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
EP2499125B1 (en) | 2009-11-12 | 2016-01-27 | Hetero Research Foundation | Process for the resolution of omeprazole |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
US20120294937A1 (en) | 2009-12-29 | 2012-11-22 | Novartis Ag | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2345408A3 (en) | 2010-01-08 | 2012-02-29 | Dr. Reddy's Laboratories Ltd. | Acid labile drug formulations |
JP5714031B2 (ja) | 2010-02-12 | 2015-05-07 | エステヴェ キミカ, エス.エー. | エソメプラゾールナトリウムのナトリウム塩の調製方法 |
US20110207779A1 (en) * | 2010-02-25 | 2011-08-25 | Glenmark Generics Ltd | Process for the preparation of esomeprazole magnesium |
AU2011299153B2 (en) | 2010-09-10 | 2014-10-30 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for concomitant treatment of theophylline and febuxostat |
CN102816149B (zh) * | 2011-06-10 | 2015-05-13 | 上海汇伦生命科技有限公司 | 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法 |
CN102807561A (zh) * | 2011-06-21 | 2012-12-05 | 寿光富康制药有限公司 | S-奥美拉唑铝盐及其制备方法和应用 |
CN102850323A (zh) * | 2011-06-30 | 2013-01-02 | 秦引林 | 一种埃索美拉唑钠的精制方法 |
CN102321071B (zh) * | 2011-07-20 | 2013-01-23 | 江苏奥赛康药业股份有限公司 | 一种高纯度埃索美拉唑钠的工业化生产方法 |
CN102911158B (zh) * | 2011-07-31 | 2015-07-22 | 连云港润众制药有限公司 | 埃索美拉唑镁的晶型 |
WO2013081566A1 (en) | 2011-11-25 | 2013-06-06 | Mahmut Bilgic | A formulation comprising benzimidazole |
EP2601947A1 (en) | 2011-12-05 | 2013-06-12 | Abo Bakr Mohammed Ali Al-Mehdar | Fixed-dose combination for treatment of helicobacter pylori associated diseases |
EP2790696A1 (en) | 2011-12-16 | 2014-10-22 | Atopix Therapeutics Limited | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
WO2013108068A1 (en) | 2012-01-21 | 2013-07-25 | Jubilant Life Sciences Limited | Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers |
CN103420978A (zh) * | 2012-05-15 | 2013-12-04 | 上海医药工业研究院 | 一种苯并咪唑类化合物的镁盐的制备方法 |
CN102657622A (zh) * | 2012-05-17 | 2012-09-12 | 康普药业股份有限公司 | 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺 |
CN102964335B (zh) * | 2012-11-13 | 2014-06-25 | 凌元敏 | 一种埃索美拉唑钠化合物及其制备方法和用途 |
CN103159737B (zh) * | 2013-04-12 | 2014-03-19 | 四川省惠达药业有限公司 | 一种埃索美拉唑钠化合物及药物组合物 |
EP3065720A1 (en) | 2013-11-04 | 2016-09-14 | Capsugel Belgium NV | Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole |
EP2929885A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
US10130618B2 (en) | 2014-04-11 | 2018-11-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
CN104045627A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种奥美拉唑纯化方法 |
CN104530003A (zh) * | 2014-06-10 | 2015-04-22 | 广东东阳光药业有限公司 | 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法 |
EP2980086B1 (en) | 2014-07-29 | 2016-06-15 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Efficient process for the preparation of esomeprazole (S)-binol complex |
CN107428726B (zh) | 2014-12-26 | 2021-03-16 | 国立大学法人东京大学 | 光学活性的质子泵抑制剂化合物的制备方法 |
ES2615637T3 (es) | 2015-03-06 | 2017-06-07 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Procedimiento mejorado para la purificación óptica del esomeprazol |
WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
CN105924430A (zh) * | 2016-06-27 | 2016-09-07 | 杭州富阳伟文环保科技有限公司 | 一种埃索美拉唑钠的精制方法 |
WO2018191210A1 (en) * | 2017-04-11 | 2018-10-18 | Mclaughlin Gormley King Company | Sabadilla oil and uses thereof |
CN108409714A (zh) * | 2018-03-29 | 2018-08-17 | 成都通德药业有限公司 | 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法 |
CA3146660A1 (en) * | 2019-07-16 | 2021-01-21 | Kindred Biosciences, Inc. | Equine esomeprazole formulations and methods of use |
WO2021039800A1 (ja) | 2019-08-29 | 2021-03-04 | 学校法人東京理科大学 | スルホキシド化合物のエナンチオマー調製方法及びエナンチオマー調製システム |
RU2726320C1 (ru) * | 2020-02-09 | 2020-07-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) | Способ определения примесных компонентов омепразола |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
US4636085A (en) * | 1982-03-16 | 1987-01-13 | Mapro Inc. | Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine |
SE8204879D0 (sv) * | 1982-08-26 | 1982-08-26 | Haessle Ab | Novel chemical intermediates |
SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
US4445708A (en) * | 1983-05-09 | 1984-05-01 | General Motors Corporation | Energy absorbing steering column for vehicles |
SE8403179D0 (sv) * | 1984-06-13 | 1984-06-13 | Haessle Ab | New compounds |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
US5075323A (en) * | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
DE4035455A1 (de) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
WO1994024867A1 (en) * | 1993-04-27 | 1994-11-10 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
CN1138534C (zh) * | 1994-07-08 | 2004-02-18 | 阿斯特拉曾尼卡有限公司 | 多单元片剂 |
SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
SE508669C2 (sv) * | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
SE9704183D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New process |
SE9900274D0 (sv) * | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
-
1993
- 1993-05-28 SE SE19939301830A patent/SE9301830D0/xx unknown
-
1994
- 1994-05-06 IS IS4161A patent/IS1854B/is unknown
- 1994-05-11 TW TW083104255A patent/TW389761B/zh not_active IP Right Cessation
- 1994-05-17 HR HR940307A patent/HRP940307B1/xx active IP Right Review Request
- 1994-05-18 LT LTIP1941A patent/LT3287B/lt not_active IP Right Cessation
- 1994-05-19 IL IL10968494A patent/IL109684A/en unknown
- 1994-05-23 ZA ZA943557A patent/ZA943557B/xx unknown
- 1994-05-25 DZ DZ940055A patent/DZ1785A1/fr active
- 1994-05-26 MA MA23521A patent/MA23210A1/fr unknown
- 1994-05-27 EP EP00108479A patent/EP1020460B1/en not_active Expired - Lifetime
- 1994-05-27 ES ES00108479T patent/ES2326404T3/es not_active Expired - Lifetime
- 1994-05-27 CZ CZ1995202A patent/CZ287876B6/cs not_active IP Right Cessation
- 1994-05-27 SI SI9420002A patent/SI9420002B/sl active Search and Examination
- 1994-05-27 MY MYPI94001349A patent/MY121192A/en unknown
- 1994-05-27 ES ES94917244T patent/ES2099047T3/es not_active Expired - Lifetime
- 1994-05-27 DE DE0652872T patent/DE652872T1/de active Pending
- 1994-05-27 JP JP50055395A patent/JP3549111B2/ja not_active Expired - Lifetime
- 1994-05-27 UA UA95018075A patent/UA60289C2/uk unknown
- 1994-05-27 DK DK00108479T patent/DK1020460T3/da active
- 1994-05-27 DK DK00108480.5T patent/DK1020461T4/en active
- 1994-05-27 AT AT94917244T patent/ATE197452T1/de not_active IP Right Cessation
- 1994-05-27 KR KR1019950700365A patent/KR100337274B1/ko not_active IP Right Cessation
- 1994-05-27 NZ NZ266915A patent/NZ266915A/en not_active IP Right Cessation
- 1994-05-27 CA CA002337581A patent/CA2337581A1/en not_active Abandoned
- 1994-05-27 EP EP94917244A patent/EP0652872B1/en not_active Revoked
- 1994-05-27 CA CA002139653A patent/CA2139653C/en not_active Expired - Lifetime
- 1994-05-27 WO PCT/SE1994/000509 patent/WO1994027988A1/en active IP Right Grant
- 1994-05-27 PL PL94307261A patent/PL178994B1/pl unknown
- 1994-05-27 YU YU31494A patent/YU49065B/sh unknown
- 1994-05-27 EP EP00108480.5A patent/EP1020461B2/en not_active Expired - Lifetime
- 1994-05-27 RU RU95105587A patent/RU2137766C1/ru active
- 1994-05-27 SG SG1996008770A patent/SG49283A1/en unknown
- 1994-05-27 DE DE69426254T patent/DE69426254T2/de not_active Revoked
- 1994-05-27 PT PT00108480T patent/PT1020461E/pt unknown
- 1994-05-27 TN TNTNSN94058A patent/TNSN94058A1/fr unknown
- 1994-05-27 ES ES00108480.5T patent/ES2326405T5/es not_active Expired - Lifetime
- 1994-05-27 CN CN94190335A patent/CN1055469C/zh not_active Expired - Lifetime
- 1994-05-27 US US08/256,174 patent/US5693818A/en not_active Expired - Lifetime
- 1994-05-27 DE DE69435220T patent/DE69435220D1/de not_active Expired - Lifetime
- 1994-05-27 HU HU9500247A patent/HU226824B1/hu active Protection Beyond IP Right Term
- 1994-05-27 SI SI9420085A patent/SI22752B/sl active Search and Examination
- 1994-05-27 PT PT94917244T patent/PT652872E/pt unknown
- 1994-05-27 SK SK101-95A patent/SK282524B6/sk not_active IP Right Cessation
- 1994-05-27 DE DE69435221T patent/DE69435221D1/de not_active Expired - Lifetime
- 1994-05-27 DK DK94917244T patent/DK0652872T3/da active
- 1994-05-27 PT PT00108479T patent/PT1020460E/pt unknown
- 1994-06-04 SA SA94140756A patent/SA94140756B1/ar unknown
- 1994-06-04 SA SA05260103A patent/SA05260103B1/ar unknown
- 1994-11-17 EE EE9400363A patent/EE03157B1/xx not_active IP Right Cessation
- 1994-12-30 LV LVP-94-266A patent/LV11034B/en unknown
-
1995
- 1995-01-23 US US08/376,512 patent/US5714504A/en not_active Expired - Lifetime
- 1995-01-24 NO NO950263A patent/NO307378B1/no not_active IP Right Cessation
- 1995-01-27 FI FI950377A patent/FI117755B/fi active Protection Beyond IP Right Term
-
1997
- 1997-05-30 GR GR970300012T patent/GR970300012T1/el unknown
-
1998
- 1998-07-17 HK HK98109228A patent/HK1008330A1/xx not_active IP Right Cessation
-
1999
- 1999-09-03 CN CN99118539A patent/CN1107503C/zh not_active Expired - Lifetime
- 1999-10-15 US US09/419,456 patent/US6143771A/en not_active Expired - Lifetime
-
2000
- 2000-11-23 HK HK00107518.8A patent/HK1028044A1/xx not_active IP Right Cessation
- 2000-11-23 HK HK00107520.4A patent/HK1028045A1/xx not_active IP Right Cessation
-
2001
- 2001-02-05 GR GR20010400191T patent/GR3035365T3/el not_active IP Right Cessation
- 2001-05-22 CY CY0100010A patent/CY2224B1/xx unknown
-
2003
- 2003-09-10 JP JP2003317637A patent/JP3959056B2/ja not_active Expired - Lifetime
- 2003-09-10 JP JP2003317639A patent/JP4039999B2/ja not_active Expired - Lifetime
-
2007
- 2007-01-02 FI FI20070002A patent/FI20070002A/fi not_active Application Discontinuation
- 2007-02-27 US US11/679,264 patent/US20080312449A1/en not_active Abandoned
-
2009
- 2009-04-02 CL CL2009000805A patent/CL2009000805A1/es unknown
- 2009-09-01 US US12/551,828 patent/US20100222591A1/en not_active Abandoned
-
2011
- 2011-06-07 NO NO2011009C patent/NO2011009I1/no unknown
- 2011-09-19 LU LU91870C patent/LU91870I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9420002B (sl) | Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin | |
NO160204C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive alkalisalter av 5-metoksy-2(((4-metoksy-3,5-dimetyl-2-pyridinyl)-metyl)-sulfinyl)-1h-benzimidazol. | |
RU2252032C2 (ru) | Новое применение соединений в качестве антибактериальных средств | |
AR010361A1 (es) | "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS" | |
GB1525958A (en) | 2-(heterocyclic substituted alkylsulphinyl)-benzimidazoles and their pharmaceutical compositions | |
EP0368640A3 (en) | Heterocyclic compounds | |
JPH02500744A (ja) | 新規な薬学的化合物 | |
FI902292A0 (fi) | Menetelmä terapeuttisesti käyttökelpoisten aryylitiatsolyylimetyyli-imidatsolien valmistamiseksi | |
ES2246903T3 (es) | Formulacion de bencimidazoles sustituidos. | |
AR007352A1 (es) | Derivados sustituidos de bencimidazol, proceso para su preparacion, formulacion farmaceutica que los contiene, y uso de dichos derivados para la manufactura de medicamentos | |
NO162556C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridylfenyl- og difenylforbindelser. | |
JP2004508295A (ja) | 抗菌剤として有用な新規な化合物 | |
ES2286408T3 (es) | Sales de alquilamonio de omeprazol e esomeprazol. | |
KR910700248A (ko) | 위산 분비 억제 효과를 갖는 화합물 및 그의 제조 방법 | |
FR2549049B1 (fr) | Nouvelles amidines, leur procede de preparation et leur application therapeutique | |
EP1020459B1 (en) | Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives | |
NO165195C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive nye derivater av 4,5-dihydro-oksazolyl-2-((2-pyridyl)-metyl-tio- eller metylsulfinyl)-benz- eller tienoimidazoler. | |
ES2232780T3 (es) | Compuesto de inclusion de s-omeprazol (esomeprazol) con ciclodextrinas. | |
KR940703840A (ko) | 치환 벤즈이미다졸, 그의 제조 방법 및 용도(substituted benzimidazoles, process for their preparation as well as their use) | |
AR047743A1 (es) | Forma de dosificacion que comprende una prodroga de un inhibidor de bomba de proton, uso de una prodroga de sulfonilo de un inhibidor de la bomba de proton para preparar dicha forma de dosificacion y producto farmaceutico que la comprende | |
US4450161A (en) | Pyrimidone salt and its preparation | |
IL88124A (en) | Pharmaceutical compositions containing 2-isoxazoline and isoxazole-5-yl phosphonate derivatives, process for their preparation and some novel compounds | |
SE8503109D0 (sv) | Cyclic prodrugs of antiinflammatory oxicams | |
NO167981C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tieno(3,4-d)imidazoler. | |
SE8801907D0 (sv) | Novel pharmacological compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20091008 |